This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...

Nov. 9, 2009

Matt Onaitis

Vice President and General Counsel of Somaxon Pharmaceuticals — Solana Beach

Read more about Matthew W. Onaitis...

Stockholders awaiting action by the Food and Drug Administration on what they hope will be the next big thing couldn't be faulted for having some sleepless nights. But in Somaxon Pharmaceuticals' case, that would be most ironic.

Its new drug, Silenor, is a treatment for insomnia.

The Solana Beach-based firm is anxiously awaiting what they hope will be agency approval, possibly in early December. Standing by is Somaxon Vice President and General Counsel M... (continued)

To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
$795 for an entire year!

Already a subscriber?